Ieq Capital LLC Grows Stock Holdings in Alphatec Holdings, Inc. $ATEC

Key Points

• Ieq Capital LLC significantly increased its stake in Alphatec Holdings, Inc. by 81.2%, acquiring 28,611 additional shares, bringing its total holdings to 63,840 shares valued at approximately $647,000.
• Alphatec reported a revenue increase of 27.5% year-over-year, achieving $185.54 million for the latest quarter, and exceeded EPS estimates by $0.08.
• Alphatec's shares have seen strong interest from institutional investors, who hold approximately 66.35% of the stock, with major firms like Vanguard and Royal Bank of Canada increasing their stakes significantly.

Ieq Capital LLC grew its position in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 81.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 63,840 shares of the medical technology company's stock after purchasing an additional 28,611 shares during the period. Ieq Capital LLC's holdings in Alphatec were worth $647,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of ATEC. Comerica Bank raised its position in shares of Alphatec by 66.8% in the fourth quarter. Comerica Bank now owns 3,116 shares of the medical technology company's stock worth $29,000 after acquiring an additional 1,248 shares during the period. Larson Financial Group LLC acquired a new position in Alphatec in the first quarter valued at $54,000. Lazard Asset Management LLC acquired a new position in Alphatec during the fourth quarter worth about $76,000. State of Wyoming purchased a new stake in shares of Alphatec in the fourth quarter valued at about $86,000. Finally, Wexford Capital LP purchased a new position in shares of Alphatec during the fourth quarter valued at approximately $95,000. Institutional investors own 66.35% of the company's stock.

Insiders Place Their Bets

In other news, EVP Craig E. Hunsaker sold 10,876 shares of the business's stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $15.33, for a total transaction of $166,729.08. Following the sale, the executive vice president directly owned 1,389,142 shares of the company's stock, valued at $21,295,546.86. The trade was a 0.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, General Counsel Tyson Eliot Marshall sold 18,092 shares of the business's stock in a transaction dated Tuesday, August 5th. The stock was sold at an average price of $14.91, for a total value of $269,751.72. Following the completion of the sale, the general counsel directly owned 438,331 shares of the company's stock, valued at $6,535,515.21. This represents a 3.96% decrease in their position. The disclosure for this sale can be found here. Insiders sold 510,247 shares of company stock worth $7,627,527 over the last 90 days. Insiders own 22.80% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on ATEC. Barclays reiterated an "overweight" rating and issued a $22.00 price objective (up from $21.00) on shares of Alphatec in a research report on Monday, August 4th. Lake Street Capital raised Alphatec to a "buy" rating and set a $18.00 target price for the company in a research note on Monday, June 16th. Wall Street Zen raised Alphatec from a "hold" rating to a "buy" rating in a research note on Sunday. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and set a $20.00 target price on shares of Alphatec in a research report on Friday, August 1st. Six investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Alphatec has an average rating of "Buy" and an average price target of $18.50.

Alphatec Price Performance

Shares of NASDAQ:ATEC traded down $0.13 during midday trading on Monday, reaching $16.28. 568,046 shares of the company's stock traded hands, compared to its average volume of 2,069,713. Alphatec Holdings, Inc. has a 1 year low of $4.88 and a 1 year high of $16.70. The company has a debt-to-equity ratio of 23.22, a quick ratio of 1.77 and a current ratio of 2.88. The company has a fifty day simple moving average of $13.38 and a two-hundred day simple moving average of $11.93. The company has a market cap of $2.41 billion, a P/E ratio of -14.40 and a beta of 1.02.

Alphatec (NASDAQ:ATEC - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The medical technology company reported $0.02 earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $0.08. The company had revenue of $185.54 million during the quarter, compared to analysts' expectations of $178.85 million. Alphatec had a negative return on equity of 1,657.19% and a negative net margin of 24.33%.The firm's revenue for the quarter was up 27.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.29) earnings per share. Alphatec has set its FY 2025 guidance at EPS. Equities analysts predict that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.